drugset / Trial / NCT03048110

Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction

NCT03048110

Phase 1 Completed 15 enrolled Bayer Orion Corporation, Orion Pharma · collab
NaSingle-groupOpen-labelOther

Summary

Evaluate the effect of a probe CYP3A4 inhibitor and inducer on the pharmacokinetics of BAY1841788 (ODM-201)

Timeline

Start
2017-02-15
Primary completion
2017-05-04
Completion
2017-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Darolutamide Other / unclassified 600 mg
Subject Itraconazole Small molecule 200 mg
Subject Rifampin Small molecule 600 mg

Indications

No indication recorded.